Kibion has been acquired by private investors
Uppsala, Sweden, April 30th, 2015
Kibion AB, the market leader for the diagnosis of the gastric ulcer bacterium Helicobacter pylori, offering the products Heliprobe® System, Diabact® UBT and IRIS™, has today been sold to a team of Swedish investors and business developers. The team has a solid background as owners and business leaders in the fields of diagnostics and treatment of gastroenterological diseases.
The last 2-3 years, Kibion’s focus, under the ownership of Orexo AB, has been to establish profitable growth which now is achieved. The new owners want to further strengthen Kibion’s commercial capabilities through investments on key markets by a new strategic commercial plan.
Kibion strengthens its market position
With the new instrument IRIS™ Dynamic, which will be available for the market during the second quarter this year, Kibion offers a complete integrated system with a user-friendly large touch screen. The system can be up scaled for increased throughput based on the need of the laboratory, hospital or clinic.
In combination with Heliprobe® System, Kibion will strengthen its position as the only provider of two validated and clinically proved Urea Breath Test systems.
“Now is the right time to invest in Kibion to accelerate growth and create increased value for patients, doctors and business partners”, said Petter Bäckgren who will remain as President and CEO of the KIBION Group.
The new owners and board members are; Håkan Björklund (Astra, Nycomed, Coloplast, Lundbeck, Atos Medical), Torbjörn Koivisto (Moberg Pharma), Magnus Lundberg (Pharmacia, Chiron, Phadia, Onyx Pharmaceutical, ConvaTec, Atos Medical) and Anders Lundmark (Phadia, Antrad Medical, Bioservo Technologies), who also will be acting as Chairman. The CEO of Kibion AB, Petter Bäckgren, will also invest in the company and becomes one of the owners.
For further information, please contact:
Petter Bäckgren, President and CEO of the KIBION Group
Tel: +46 (0)70-555 69 97